Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023 Full year 2024 CAPLYTA net product sales were $680.5 million, ...
The US FDA has approved lumateperone (Caplyta, Johnson & Johnson) for use as adjunctive therapy with antidepressants for the treatment of adults with major depressive disorder (MDD). The approval of ...
Intra-Cellular Therapies, Inc. reported that CAPLYTA's net product sales reached $199.2 million in the fourth quarter of 2024, a significant 51% increase compared to the previous year, contributing to ...
The 43 rd annual J.P. Morgan Healthcare Conference got off to a newsy start Jan. 13 in San Francisco, with Johnson & Johnson’s CEO Joaquin Duato addressing a just-announced $14.6 billion purchase of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results